Daiwa Securities Group
AIMT

Daiwa Securities Group’s Aimmune Therapeutics AIMT Stock Holding History

Daiwa Securities Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-357
Closed -$12K – 1315
2020
Q3 		$12K Hold
357
– – ﹤0.01% 1032
2020
Q2 		$5K Hold
357
– – ﹤0.01% 1113
2020
Q1 		$5K Hold
357
– – ﹤0.01% 1109
2019
Q4 		$12K Sell
357
-38
-10% -$1.06K ﹤0.01% 1049
2019
Q3 		$8K Hold
395
– – ﹤0.01% 1048
2019
Q2 		$8K Hold
395
– – ﹤0.01% 1071
2019
Q1 		$9K Buy
395
+114
+41% +$2.68K ﹤0.01% 1042
2018
Q4 		$7K Hold
281
– – ﹤0.01% 1034
2018
Q3 		$8K Hold
281
– – ﹤0.01% 1062
2018
Q2 		$8K Hold
281
– – ﹤0.01% 1070
2018
Q1 		$9K Buy
+281
New +$9.89K ﹤0.01% 1042

Daiwa Securities Group's AIMT Position: Q4 2020 in Review

Daiwa Securities Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 357 shares — an estimated $12K sold.

Daiwa Securities Group first reported a position in AIMT in Q1 2018 and held it in 11 quarters. The position peaked at $12K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Daiwa Securities Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Daiwa Securities Group sold 357 Aimmune Therapeutics shares in Q4 2020, an estimated $12K.
  • Daiwa Securities Group first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 11 quarters.
  • Daiwa Securities Group's Aimmune Therapeutics position peaked at $12K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Daiwa Securities Group's 13F filing for Q4 2020, filed 4 Feb 2021.